Skip to main content

Erosive Osteoarthritis

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

EffRx Pharmaceuticals
EffRx PharmaceuticalsSwitzerland - Freienbach
1 program
1
Alendronate Effervescent Oral TabletPhase 21 trial
Active Trials
NCT04403698Completed30Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EffRx PharmaceuticalsAlendronate Effervescent Oral Tablet

Clinical Trials (1)

Total enrollment: 30 patients across 1 trials

NCT04403698EffRx PharmaceuticalsAlendronate Effervescent Oral Tablet

The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover

Start: Nov 2019Est. completion: Mar 202230 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.